Clinical trial
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian…
NCT00019552 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019552 |
|---|---|
| Title | Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer |
| Official title | A Phase II Study of MGI-114 in Patients With Recurrent or Persistent Epithelial Ovarian Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | irofulven |
| Start date | Sep 1, 1998 |
| Completion | Apr 1, 2004 |
| First posted | Apr 13, 2004 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: